Physician profile
Eric Wigton
NPI 1396926424
$12,299.12
in general payments reported to CMS, 2019-2025
24 companies · $1,837 in 2025
The $1,837 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,101 · 2020: $2,625 · 2021: $914 · 2022: $813 · 2023: $810 · 2024: $1,199 · 2025: $1,837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,846.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,984.40 | 2019-2022 | |
| Abbvie INC. | $1,743.33 | 2022-2025 | Lumigan, Alphagan P, Durysta |
| Alcon Vision LLC | $1,635.52 | 2019-2025 | Clareon, Rocklatan, Rhopressa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $416.05 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $339.64 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Aerie Pharmaceuticals, INC. | $333.89 | 2019-2021 | |
| Ivantis, INC | $326.86 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $247.15 | 2019-2024 | Cequa |
| Novartis Pharmaceuticals Corporation | $196.40 | 2020-2023 | |
| Rxsight INC | $144.11 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Shire North American Group INC | $138.61 | 2019 | |
| Oyster Point Pharma, INC. | $121.70 | 2022-2024 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $119.93 | 2021-2023 | Acthar |
| Thea Pharma INC. | $103.18 | 2023-2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $95.73 | 2021-2024 | Dextenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $94.97 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $91.97 | 2021-2024 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Dompe US, INC. | $75.20 | 2025 | Oxervate |
| Amgen INC. | $22.72 | 2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $18.09 | 2024 | Tecnis Iol |
| Sight Sciences, INC. | $14.53 | 2019 | |
| Eyevance Pharmaceuticals LLC | $13.90 | 2020 | |
| Harrow Eye, LLC | $13.12 | 2024 | Vevye |
| Biotissue Holdings INC. | $8.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Wigton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.